ACADIA Pharmaceuticals Inc. (ACAD)
$
21.57
-0.72 (-3.34%)
Key metrics
Financial statements
Free cash flow per share
0.2974
Market cap
3.7 Billion
Price to sales ratio
3.6923
Debt to equity
0.0732
Current ratio
2.8789
Income quality
0.6508
Average inventory
22.4 Million
ROE
0.3532
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of small molecule drugs to address the unmet medical needs in central nervous system disorders. The company’s net income ratio is 0.24 reflecting its profitability margin. Despite the investment in research and development, the company reported selling, general, and administrative expenses of $488,428,000.00 indicating its operational overhead costs. The net total of other income and expenses is $27,281,000.00 reflecting non-core financial activities. Furthermore, the company incurred an income tax expense of $31,624,000.00 indicating its tax obligations. The income before tax ratio is 0.27 reflecting the pre-tax margin. ACADIA offers NUPLAZID (pimavanserin) for treating hallucinations and delusions associated with Parkinson's disease psychosis, while its pipeline includes pimavanserin, currently under phase 3 development for Alzheimer's disease psychosis and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for Rett syndrome; ACP-044, an innovative first-in-class orally administered non-opioid analgesic under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, undergoing phase 1 development for schizophrenia and cognitive dysfunction in Alzheimer's. Founded in 1993, ACADIA is headquartered in San Diego, California. Currently, the stock is affordable at $22.29 making it suitable for budget-conscious investors. Additionally, the stock has a high average trading volume of 2,090,866.00 indicating strong liquidity. With a mid-range market capitalization of $3,609,998,340.00 the company is regarded as a steady performer. ACADIA Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth in areas that address critical health challenges.
Is ACADIA Pharmaceuticals Inc. (ACAD) a good investment?
Investing in ACADIA Pharmaceuticals Inc. (ACAD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
What is ACADIA Pharmaceuticals Inc. (ACAD)'s stock forecast?
Analysts predict ACADIA Pharmaceuticals Inc. stock to fluctuate between $13.40 (low) and $25.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ACADIA Pharmaceuticals Inc.'s market capitalization?
As of 2025-05-30, ACADIA Pharmaceuticals Inc.'s market cap is $3,609,998,340, based on 167,362,000 outstanding shares.
How does ACADIA Pharmaceuticals Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., ACADIA Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ACADIA Pharmaceuticals Inc. (ACAD) stock?
To buy ACADIA Pharmaceuticals Inc. (ACAD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACAD. Place an order (Market, Limit, etc.).
What is the best time to invest in ACADIA Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did ACADIA Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $957,797,000 | EPS: $1.37 | Growth: -470.27%.
Where can I find ACADIA Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.acadia-pharm.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ACADIA Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for ACADIA Pharmaceuticals Inc. stock?
All-time high: $52.80 (2021-02-10) | All-time low: $12.24 (2022-06-21).
What are the key trends affecting ACADIA Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
benzinga.com
ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday.
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), Acadia's drug for the treatment of Parkinson's Disease Psychosis. In today's order, the Court ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated.
zacks.com
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
zacks.com
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
seekingalpha.com
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Al Kildani - SVP of IR & Corporate Communications Catherine Owen Adams - CEO Tom Garner - COO Elizabeth Thompson - EVP and Head of R&D Mark Schneyer - EVP and CFO Conference Call Participants Ritu Baral - TD Cowen Tessa Romero - JPMorgan Ash Verma - UBS Elaine Kim - Canter Basma Radwan - Leerink Partners David Huang - Deutsche Bank Tazeen Ahmad - Bank of America Yatin Suneja - Guggenheim Joel Beatty - Baird Sumant Kulkarni - Canaccord Genuity Malcolm Hoffman - BMO Capital Markets Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Lauren Cannon, and I'll be your coordinator for today.
zacks.com
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
zacks.com
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
businesswire.com
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age an.
zacks.com
Acadia Pharmaceuticals (ACAD) came out with fourth-quarter earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago.
See all news
